<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81715">
  <stage>Registered</stage>
  <submitdate>14/07/2000</submitdate>
  <approvaldate>14/07/2000</approvaldate>
  <actrnumber>ACTRN12607000112460</actrnumber>
  <trial_identification>
    <studytitle>Radiotherapy versus radiotherapy plus chemotherapy in early stage follicular lymphoma</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 99.03 - A randomised multicentre trial of involved field radiotherapy versus involved field radiotherapy plus chemotherapy (cyclophosphamide, vincristine Prednisolone) in combination with Rituximb (Mabthera) for stage I-II low grade follicular lymphoma to improve progression free survival</scientifictitle>
    <utrn />
    <trialacronym>TROG 99.03</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR325</secondaryid>
    <secondaryid>ClinicalTrials.gov: NCT00115700</secondaryid>
    <secondaryid>The Australasian Leukaemia and Lymphoma Group: ALLG NHLLOW5</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Stage I-II low grade follicular lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: Involved field radiotherapy 30-36Gy. Daily fractions of 1.5-2.0 Gy. Will be given 5 days per week. Cyclophosphamide 1000mg per metre squared IV on day 1. Vincristine 1.4mg per metre squared IV on day 1, Prednisolone 50mg per metre squared orally for days 1-5, Rituximab 375mg per metre squared IV infusion day 1. A total of six 21 day cycles of CVP plus rituximab should be administered.</interventions>
    <comparator>Arm 2: Involved field radiotherapy 30-36Gy. Daily fractions of 1.5-2.0 Gy. Will be given 5 days per week for 3 weeks. Involved field radiotherapy: radiotherapy of the known disease region with a suitable margin (+/- nearby univolved lymph node groups are irradiated)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression free survival. Period from date of randomisation to first progression of disease or death from any cause.</outcome>
      <timepoint>Follow-up visits will occur as follows: 3-monthly intervals for 2 years, commencing 3 months after the completion of protocol treatment, then 6-monthly until 5 years, then annually thereafter until 10 years after the end of accrual.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Pre- and post-treatment prevalence of the t(14;18) translocation in peripheral blood and bone marrow between arms.</outcome>
      <timepoint>Measured by Polymerase Chain Reaction (PCR) before treatment commences, at 1 year and upon first relapse. t(14;18): means translocation of a section of chromosome 18 to a section of chromosome 14. This results in dysregulated expression in bcl-2 gene. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Overall survival.</outcome>
      <timepoint>Follow-up visits will occur as follows: 3-monthly intervals for 2 years, commencing 3 months after the completion of protocol treatment, then 6-monthly until 5 years, then annually thereafter until 10 years after the end of accrual.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Location of first relapse. If it is nodal, extranodal or systemic.</outcome>
      <timepoint>Follow-up visits will occur as follows: 3-monthly intervals for 2 years, commencing 3 months after the completion of protocol treatment, then 6-monthly until 5 years, then annually thereafter until 10 years after the end of accrual. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Time to histologic progression. </outcome>
      <timepoint>Follow-up visits will occur as follows: 3-monthly intervals for 2 years, commencing 3 months after the completion of protocol treatment, then 6-monthly until 5 years, then annually thereafter until 10 years after the end of accrual.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Adult patients (= 18 years old) with histologically documented follicular lymphoma, grade 1", "follicular lymphoma, grade 2", or "follicular lymphoma, grade 3a" diagnosed following an excisional, incisional or generous core biopsy (i.e. an FNA alone is insufficient).
- Disease limited to stages I and II after adequate staging
- Anticipated life expectancy &gt; 5 years
- Given written informed consent
- Been assessed by a radiation oncologist and a medical oncologist/ haematologist
- White Cell Count (WCC) &gt; 3.0 x 10^9/L, platelet count &gt; 100 x 10^9/L, serum creatinine &lt; 0.15 mmol/L
- Ability to commence radiotherapy within 6 weeks of randomisation
- Women using effective contraception, are not pregnant and agree not to become pregnant during participating in the trial and during the 12 months thereafter. Men agree not to father a child during participation in the trial and during the 12 months thereafter.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Received previous systemic cytotoxic chemotherapy.
- Received previous radiotherapy, (except superficial radiation therapy for non-melanoma skin cancers).
- Received previous immunotherapy
- A medical contraindication to radiotherapy or rituximab.
- Any previous or concurrent malignancy other than curatively treated non-melanoma skin cancer, level 1 malignant melanoma, or in situ cervical cancer, unless disease and treatment-free for 5 years.
- Such extensive involvement of the thorax that treatment with radiation therapy alone would be hazardous because of excessive lung irradiation, even if a shrinking field technique were employed.
- Patients who have known human immuno-deficiency virus (HIV) infection or active hepatitis B (HBV)
- Treatment within a clinical study within 30 days prior to study entry
- Suspected or confirmed pregnancy. Must not be lactating.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Stratification: Centre, Stage (I/II), Age (&lt;60/&gt;=60), Whether PET staged. Simple randomisation by computer</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/02/2000</anticipatedstartdate>
    <actualstartdate>14/02/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate>12/07/2012</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>150</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,TAS,WA</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Michael MacManus</primarysponsorname>
    <primarysponsoraddress>Peter MacCallum Cancer Centre Department of Radiation Oncology Locked Bag 1 A'Beckett Street VIC 8006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Council Victoria</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>AMGEN</fundingname>
      <fundingaddress>Level 7, 123 Epping Road
North Ryde, NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Trans Tasman Radiation Oncology Group (TROG)</sponsorname>
      <sponsoraddress>Edith St Waratah NSW 2298</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients with stage I and II low grade follicular lymphoma are randomised between standard therapy (involved field radiotherapy) and investigational therapy (involved field radiotherapy plus chemotherapy). The main endpoint is progression free survival but overall survival and the influence of t(14;18) status will also be studied.</summary>
    <trialwebsite>www.trog.com.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Hospital</ethicname>
      <ethicaddress>Heidelberg, VIC</ethicaddress>
      <ethicapprovaldate>11/08/1999</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress>Auckland, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Canberra Hospital</ethicname>
      <ethicaddress>Garran, ACT</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Premion Tugun</ethicname>
      <ethicaddress>Tugun, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Barwon Health - Andrew Love Cancer Care Centre, Geelong Hospital</ethicname>
      <ethicaddress>Geelong, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston Hospital</ethicname>
      <ethicaddress>Launceston, TAS</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater QRI</ethicname>
      <ethicaddress>South Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Murray Valley Private Hospital</ethicname>
      <ethicaddress>Wodonga, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Calvary Mater Newcastle</ethicname>
      <ethicaddress>Waratah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>Melbourne, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales (Hong Kong)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Hong Kong</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress>Randwick, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress>Wooloongabba, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Margaret (Toronto)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Queen Elizabeth</ethicname>
      <ethicaddress>Woodville, SA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress>Adelaide, SA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress>Herston, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress>Nedlands, WA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Hospital</ethicname>
      <ethicaddress>Kogarah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Waikato Hospital</ethicname>
      <ethicaddress>Hamilton, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress>Wellington, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Wentworthville, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress>Christchurch</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Michael MacManus</name>
      <address>Peter MacCallum Cancer Centre
Department of Radiation Oncology
Locked Bag 1 A'Beckett Street VIC 8006</address>
      <phone>+61 3 9656 1111</phone>
      <fax />
      <email>Michael.MacManus@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Bev McClure</name>
      <address>Peter MacCallum Cancer Centre
Department of Radiation Oncology
Locked Bag 1
A'Beckett Street VIC 8006</address>
      <phone>+61 3 9656 1266</phone>
      <fax />
      <email>Bev.McClure@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>TROG Administrator</name>
      <address>TROG Cancer Research
Central Operations Office
PO Box 88
Waratah NSW 2298</address>
      <phone>+61 2 4014 3910  </phone>
      <fax>+61 2 4014 3902</fax>
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Michael MacManus</name>
      <address>Peter MacCallum Cancer Centre Department of Radiation Oncology Locked Bag 1 A'Beckett Street VIC 8006  </address>
      <phone>+61 3 9656 1111  </phone>
      <fax />
      <email>Michael.MacManus@petermac.org  </email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>